• 제목/요약/키워드: Growth hormone therapy

검색결과 84건 처리시간 0.023초

마사지요법이 저체중아의 성장, 생리적 변화 및 모.영아 상호작용에 미치는 효과 (Effects of the Massage Therapy on Weight, Stress Hormone and Mother - Infant Interaction)

  • 김미예;김선희
    • 부모자녀건강학회지
    • /
    • 제3권1호
    • /
    • pp.1-14
    • /
    • 2000
  • The Low Birth Weight infant birth rate in this country is a little more than 15 percent and is being increased. The survival rate of Low Birth Weight infant is over 90 percent and recently the rate runs is getting. However, because of the high risk of Low Birth Weight infant for handicap in growth, a preventive nursing intervention program for Low Birth Weight infant and their mother is considered to be necessary. Touch and massage, thus sensory stimulation has been considered to be important ensuring a normal growth of Low Birth Weight infant During the past decades sensory stimulation program has been used for premature and Low Birth Weight infants. Recently a study on the sensory stimulation for Low Birth Weight infants has bee n done in this country. Mother and infant relationship has a great influence on child's development. Especially, mother and infant interaction during one year after birth plays important role in child's social. affective and cognitive developments. But in the study of Low Birth Weight infants, the mother and infant interaction has been rare yet. However, there was no study effectiveness of the sensory stimulation on mother and infant interaction. In this respect, this study based on the importance of the nursing intervention, is intended to measure the effectiveness of the massage therapy in the aspects of weight, daily feeding amount, cortisolurine stress hormone and mother and infant interactions. This study has been conducted on the nonequivalent control group pretestposttest design in quasi experimental basis and Low Birth Weight infants from NICU of two Medical University Hospitals located in Taegu Metropolitan were selected in experimental group of 21 infants and control group of 20 infants. Data has been collected from May 1, 1999 to September 5, 2000. For the experimental group Field's sensory stimulation(tactile and kinesthetic stimulation) was applied 2 times a day for 10 days(10:00 - 11:00 hours in the morning and 19:00 - 20:00 in the afternoon) by nurse and mother. The electronic indicator scale (Cas Co. Korea) was used to measure infant's body weight. To determine urine cortisol concentration level under stress, rad immuno assay method was used. And to determine mother and infant interactions during feeding, tools developed by Kim Mi-Ye (1999) were used. Collected data were analyzed with SAS program using x-test, t-test, paired t-test and repeated measures ANOVA. Findings were as follows : 1. For the daily mean weight gain, the experimental group showed little higher than the control group, even though, there was no Statistically significant differences between two groups. 2. For the amount of daily mean feeding, the experimental group showed little higher than the control group, while there was no Statistically significant differences between two groups. 3. The level of wine cortisol concentration was increased in both groups, while no Statistical significance was shown between the two groups. 4. Mothers in experimental group were more likely to have higher mean scores in mother and infant interaction during feeding than mothers in the control group. Statistical significance was shown between the two groups(t= 5.78, P=.001). In conclusion, the massage therapy in this study showed with regard to even though through there was no statistically significance in the weight gain and urine stress hormone concentration. there was Statistical significantly higher in the mother and infant interaction during feeding. Based on the result of this study, it is considered that the massage therapy should be applied clinical practice and home to help a developmental growth and interaction of Low Birth Weight infants and mothers during the period of recovery.

  • PDF

소아 수모세포종 환자에서 치료 후의 내분비적 장애와 성장변화 (Endocrine dysfunction and growth in children with medulloblastoma)

  • 윤인석;서지영;신충호;김일한;신희영;양세원;안효섭
    • Clinical and Experimental Pediatrics
    • /
    • 제49권3호
    • /
    • pp.292-297
    • /
    • 2006
  • 목 적 : 소아 수모세포종은 수술과 중추신경계 방사선조사 그리고 항암화학요법의 병합치료로 장기 생존율의 향상을 가져왔으나 성장호르몬결핍을 포함한 여러 내분비적 장애가 잘 발생하기에, 본 저자들은 수모세포종 치료 후 내분비적 장애와 성장변화를 관찰하고 해당 호르몬 치료의 성과를 분석하였다. 방 법 : 1986-2004년까지 서울대학교병원에서 수모세포종 치료를 마친 후 소아내분비 외래를 방문한 37명(남아 24명, 여아 13명)을 대상으로 내분비 장애와 성장변화에 대하여 분석하였다. 결 과 : 성장속도가 4 cm/yr 미만인 환자 중 16명에서 성장호르몬자극검사가 시행되었고 14명(전체환자 중 37.8%)이 성장호르몬결핍증으로 진단받았으며(완전 5명, 부분 9명), 2명의 환자는 신경분비장애로 의심되었다. 성장호르몬결핍증 환자군과 성장호르몬결핍이 없는 군 모두에서 방사선치료 전후의 키 표준편차 점수는 모두 유의한 감소를 보였으며(P<0.001), 성장호르몬결핍이 있는 12명과 신경분비장애가 있는 1명의 환자에게서 성장호르몬 치료를 시작하였다. 치료 전 골연령은 $9.3{\pm}4.7$세로 역연령에 비해 2.1세 저하되어 있었다. 치료 전 성장속도는 $3.4{\pm}1.2cm/yr$에서 1년째 $5.4{\pm}2.9cm/yr$로 유의하게 증가하였으나 키표준편차점수는 치료 전과 치료 후 유의한 변화가 없었다. 전체 37명 중 12명(32.4%)이 일차성 갑상선기능저하증으로 갑상선호르몬 치료를 받았다. 또한 다른 6명(16.2%)에서는 보상성 갑상선기능저하증이 의심되었다. 1명의 환자에서 방사선 치료종료 7년 후에 갑상선암이 발생하여 갑상선 전절제술을 시행 받은 후 갑상선호르몬을 복용 중이다. 성선자극호르몬결핍 1명(2%), 성선부전증이 2명(4%) 진단되었다. 결 론 : 수모세포종 치료 후 대부분 성장장애가 관찰되며 주로 성장호르몬결핍증과 척수방사선조사 등에 기인한다. 성장호르몬결핍증과 갑상선기능저하증 및 다른 내분비적 장애가 발생할 수 있으므로 지속적인 정기 추적 관찰 및 적절한 치료가 필요하다.

Intraovarian vascular enhancement via stromal injection of platelet-derived growth factors: Exploring subsequent oocyte chromosomal status and in vitro fertilization outcomes

  • Wood, Samuel H.;Sills, E. Scott
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제47권2호
    • /
    • pp.94-100
    • /
    • 2020
  • The inverse correlation between maternal age and pregnancy rate represents a major challenge for reproductive endocrinology. The high embryo ploidy error rate in failed in vitro fertilization (IVF) cycles reflects genetic misfires accumulated by older oocytes over time. Despite the application of different follicular recruitment protocols during IVF, gonadotropin modifications are generally futile in addressing such damage. Even when additional oocytes are retrieved, quality is frequently poor. Older oocytes with serious cytoplasmic and/or chromosomal errors are often harvested from poorly perfused follicles, and ovarian vascularity and follicular oxygenation impact embryonic chromosomal competency. Because stimulation regimens exert their effects briefly and immediately before ovulation, gonadotropins alone are an ineffective antidote to long-term hypoxic pathology. In contrast, the tissue repair properties (and particularly the angiogenic effects) of platelet-rich plasma (PRP) are well known, with applications in other clinical contexts. Injection of conventional PRP and/or its components (e.g., isolated platelet-derived growth factors as a cell-free substrate) into ovarian tissue prior to IVF has been reported to improve reproductive outcomes. Any derivative neovascularity may modulate oocyte competence by increasing cellular oxygenation and/or lowering concentrations of intraovarian reactive oxygen species. We propose a mechanism to support intrastromal angiogenesis, improved follicular perfusion, and, crucially, embryo ploidy rescue. This last effect may be explained by mRNA upregulation coordinated by PRP-associated molecular signaling, as in other tissue systems. Additionally, we outline an intraovarian injection technique for platelet-derived growth factors and present this method to help minimize reliance on donor oocytes and conventional hormone replacement therapy.

체외수정시술을 위한 성선자극호르몬 과배란유도에 Poor Response를 나타낸 환자에서 GnRH Analogue의 사용 (GnRH Analogue in Controlled Ovarian Hyperstimulation for Gonadotropin Poor Responder)

  • 김선행;이희경;구병삼
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제20권1호
    • /
    • pp.37-43
    • /
    • 1993
  • In 27 patients with the past history of poor response to the gonadotropin superovulation induction due to poor follicular growth or permature surge of endogenous luteinizing hormone, the effectiveness of pituitary supperssion with the gonadotropin releasing hormone agonist(GnRH-a) in in vitro fertilization(IVF) program was evaluated in 43 cycles using a combination regimen of D-Trp-6 LHRH(Decapeptyl, Ferring)and FSH/hMG from June, 1989 to August, 1990 at Korea University Hospital IVF Clinic. At midluteal phase of menstrual cycle, Decapeptyl-CR was administered by long-term protocol to minimize initial agonistic effect of endogenous gonadotropins. After the confirmation of pituitary suppression, about 2-3 weeks after GNRH-a administration, ovarian follicle growth was stimulated with FSH/hMG and followed by transvaginal ultrasonic measurement of follicle size and by monitoring of serm E2 and LH if necessary. When compared with the control group stimulated with gonadotropin regimen only, the cancellation rate and occurrence rate of premature LH surge during gonadotropin treatment were significantly lower in study group(11.6% and 2.4%, respectively). There is no significant differences in the mean number of aspirated oocytes, fertilization/cleavage rate, embryo transfer(ET) rate, and mean number of embryos transferred between the two groups. The pregnancy rate per treatment cycle, 16.3%, and per ET cycle, 23.3%, were significantly higher in the study group compared with those of control group. These data suggest that GnRH-a therapy is effective for previous poor responder In gonadotropin superovulation induction for IVF.

  • PDF

Parathyroid Hormone-Related Protein Promotes the Proliferation of Patient-Derived Glioblastoma Stem Cells via Activating cAMP/PKA Signaling Pathway

  • Zhenyu Guo;Tingqin Huang;Yingfei Liu;Chongxiao Liu
    • International Journal of Stem Cells
    • /
    • 제16권3호
    • /
    • pp.315-325
    • /
    • 2023
  • Background and Objectives: Glioblastoma (GBM) is an aggressive primary brain tumor characterized by its heterogeneity and high recurrence and lethality rates. Glioblastoma stem cells (GSCs) play a crucial role in therapy resistance and tumor recurrence. Therefore, targeting GSCs is a key objective in developing effective treatments for GBM. The role of Parathyroid hormone-related peptide (PTHrP) in GBM and its impact on GSCs remains unclear. This study aimed to investigate the effect of PTHrP on GSCs and its potential as a therapeutic target for GBM. Methods and Results: Using the Cancer Genome Atlas (TCGA) database, we found higher expression of PTHrP in GBM, which correlated inversely with survival. GSCs were established from three human GBM samples obtained after surgical resection. Exposure to recombinant human PTHrP protein (rPTHrP) at different concentrations significantly enhanced GSCs viability. Knockdown of PTHrP using target-specific siRNA (siPTHrP) inhibited tumorsphere formation and reduced the number of BrdU-positive cells. In an orthotopic xenograft mouse model, suppression of PTHrP expression led to significant inhibition of tumor growth. The addition of rPTHrP in the growth medium counteracted the antiproliferative effect of siPTHrP. Further investigation revealed that PTHrP increased cAMP concentration and activated the PKA signaling pathway. Treatment with forskolin, an adenylyl cyclase activator, nullified the antiproliferative effect of siPTHrP. Conclusions: Our findings demonstrate that PTHrP promotes the proliferation of patient-derived GSCs by activating the cAMP/PKA signaling pathway. These results uncover a novel role for PTHrP and suggest its potential as a therapeutic target for GBM treatment.

프래더 윌리 증후군의 유전학적 발병 기전에 따른 표현형 및 성장 호르몬 치료 효과에 관한 연구 (Phenotype-genotype correlations and the efficacy of growth hormone treatment in Korean children with Prader-Willi syndrome)

  • 배근욱;고정민;유한욱
    • Clinical and Experimental Pediatrics
    • /
    • 제51권3호
    • /
    • pp.315-322
    • /
    • 2008
  • 목 적 : PWS의 두 가지 대표적 유전형인 미세결실형과 mUPD (15)형에서, 유전형에 따른 표현형의 차이와 성장 호르몬 투여 효과의 차이를 비교해 보고자 하였다. 방 법 : 1990년 1월부터 2007년 1월까지 서울아산병원에서 15번 염색체의 미세 결실에 대한 FISH 검사 및 메틸화-특이 PCR 검사를 통해 PWS로 확진된 53명의 환자를 대상으로 하였다. 출생시 부모의 연령, 출생 체중, PWS의 주요 표현형인 신생아 시기의 저긴장증, 수유 문제, 남아의 경우 잠복 고환, 발달 지연 및 정신 지체, 저신장, 저색소증, 사시, 척추측만증 등의 유무, 성장 호르몬 치료 전과 치료 후의 신장, 체중, 체질량 지수의 변화를 조사하였고 미세결실형 군과 mUPD(15)형 군으로 나누어 유전형에 따른 차이를 분석하였다. 결 과 : 유전학적 검사상 53명의 대상 환아 모두 미세결실형 또는 mUPD(15)형으로 진단되었으며, 미세결실형은 39명, mUPD (15)형은 14명이었다. 평균 진단 연령은 $4.51{\pm}5.19$세였다. 출생 당시 부모의 연령은 mUPD(15)형 군에서 유의하게 높았으며(P=0.0001), 저색소증(P=0.0001)과 신생아기의 수유 부전(P=0.049)은 미세결실형에서 유의하게 많았으나, 그 외의 조사된 표현형에서는 두 군 간에 통계적으로 의미 있는 차이는 없었다. 성장 호르몬은 20명의 환아[미세결실형 14명, mUPD(15)형 6명]에게 평균 $27.9{\pm}11.9$개월 동안 투여되었다. 두 유전형 간에 성장 호르몬 치료 전 및 치료 후의 신장 SDS, 체중 SDS, 체질량지수, IGF-1, IGFBP3, 신장 증가 속도, 체중 증가 속도의 값에는 의미 있는 차이가 없었다. 결 론 : PWS의 주요한 두 유전형의 비교에서, 부모의 연령은 mUPD(15)형에서 의미 있게 높았으며 신생아기 수유 부전과 저색소증은 결실형에서 의미 있게 많았다. 성장 호르몬의 치료 효과에서는 두 유전형 간에 의미 있는 반응의 차이는 없었다. 향후 두 유전자형과 다른 표현형들(예를 들면 행동, 발달, 지능 등) 과의 연관성에 관한 전향적 연구가 더 필요할 것으로 생각된다.

HER2 induces expression of leptin in human breast epithelial cells

  • Cha, Yujin;Kang, Youjin;Moon, Aree
    • BMB Reports
    • /
    • 제45권12호
    • /
    • pp.719-723
    • /
    • 2012
  • A close association between the obesity hormone leptin and breast cancer progression has been suggested. The present study investigated the molecular mechanism for enhanced leptin expression in breast cancer cells and its functional significance in breast cancer aggressiveness. We examined whether leptin expression level is affected by the oncoprotein human epidermal growth factor receptor2 (HER2), which is overexpressed in ~30% of breast tumors. Here, we report, for the first time, that HER2 induces transcriptional activation of leptin in MCF10A human breast epithelial cells. We also showed that p38 mitogen-activated protein kinase signaling was involved in leptin expression induced by HER2. We showed a crucial role of leptin in the invasiveness of HER2-MCF10A cells using an siRNA molecule targeting leptin. Taken together, the results indicate a molecular link between HER2 and leptin, providing supporting evidence that leptin represents a target for breast cancer therapy.

성장장애 한의표준임상진료지침 개발을 위한 한의사 인식조사 (A Survey on Korean Medicine Doctors' Recognition for Developing Korean Medicine Clinical Practice Guideline for Growth Disorders)

  • 안혜리;심수보;이혜림
    • 대한한방소아과학회지
    • /
    • 제35권4호
    • /
    • pp.1-15
    • /
    • 2021
  • Objectives The purpose of this study is to provide data for development of the korean medicine (KM) clinical practice guidelines (CPG) for growth disorder (GD) by identifying the awareness and knowledge needs of KM doctors (KMD) through online survey. Methods Survey questionnaire was produced by referring to the previous recognition survey studies for clinical KMDs. The survey questionnaire was composed 18 questions regarding the current status of clinical care for GD, clinician's knowledge level about GD, and other details that clinicians use during practice. The survey was conducted from January 2021 to March 2021. An online survey was conducted on 101 KMDs from the association of pediatrics of KM. Results According to the survey, 96 respondents (40.3%) said the causation of GD without growth hormone deficiency needs to be included in CPG. 96 (23.5%) of the respondents wishes to utilize percentile in diagnosis and evaluation of the growth assessment. 24.7% of the clinicians were using the herbal medicine treatment. Currently, when treating with KM for GD, herbal medicine (100%) is the most widely used, followed by acupuncture (77.6%), and moxibustion (36.7%). In terms of a complex treatment, growth therapy efficacy (26.8%) is shown to be the most important factor to consider and needed to be included in CPG for the complex treatment, and diet (22.3%) is also considered to be important in GD. Conclusions In this study, we were able to understand the clinical KMDs' perception of GD, knowledge level, and the requirements in the CPG. The results of this study will provide the basic data for development of CPG for GD.

전이성 혈관주위세포종 환자에서 발생한 저혈당을 프레드니솔론으로 치료한 1예 (Treatment of Hemangiopericytoma-Associated Hypoglycemia with Glucocorticoid Therapy)

  • 박성우;김동근;김명진;장효진;손세훈;고성애;이하영;김민경;이경희;현명수
    • Journal of Yeungnam Medical Science
    • /
    • 제28권1호
    • /
    • pp.77-83
    • /
    • 2011
  • Non-islet cell tumor-induced hypoglycemia (NICTH) is associated with mesenchymal tumor types, including hemangiopericytoma, fibrosarcoma, mesothelioma, and neurofibroma, as well as carcinoma of the liver, adrenal glands, and kidneys. Non- islet cell tumors induce hypoglycemia by overproducing an abnormal form of insulin-like growth factor II (IGF m. Complete removal of the tumor or reduction of the tumor mass is a successful therapeutic strategy in cases of NICTH. However, if the tumor re-grows, curative resection is nearly impossible, and hypoglycemia occurs repeatedly. Glucocorticoids are effective in terms of long-term relief from hypoglycemia through promotion of gluconeogenesis in the liver, tumor suppression, production of 'big'-IGF-II, and correction of the attendant biochemical abnormalities involving the growth hormone (GH)-IGF axis. We found that administration of corticosteroid therapy to a patient suffering from NICTH resulted in improvement of hypoglycemia associated symptoms.

  • PDF

From diagnosis to treatment of mucopolysaccharidosis type VI: A case report with a novel variant, c.1157C>T (p.Ser386Phe), in ARSB gene

  • Yoo, Sukdong;Lee, Jun;Kim, Minji;Yoon, Ju Young;Cheon, Chong Kun
    • Journal of Genetic Medicine
    • /
    • 제19권1호
    • /
    • pp.32-37
    • /
    • 2022
  • Mucopolysaccharidosis type VI (MPS VI) is an autosomal recessive lysosomal disorder caused by the deficiency of arylsulfatase B due to mutations in the ARSB gene. Here, we report the case of a Korean female with a novel variant of MPS VI. A Korean female aged 5 years and 8 months, who is the only child of a healthy non-consanguineous Korean couple, presented at our hospital for severe short stature. She had a medical history of umbilical hernia and recurrent otitis media. Her symptoms included snoring and mouth breathing. Subtle dysmorphic features, including mild coarse face, joint contracture, hepatomegaly, and limited range of joint motion, were identified. Radiography revealed deformities, suggesting skeletal dysplasia. Growth hormone (GH) provocation tests revealed complete GH deficiency. Targeted exome sequencing revealed compound heterozygous mutations in the ARSB genes c.512G>A (p.Gly171Asp; a pathogenic variant inherited from her father) and c.1157C>T (p.Ser386Phe; a novel variant inherited from her mother in familial genetic testing). Quantitative tests revealed increased urine glycosaminoglycan (GAG) levels and decreased enzyme activity of arylsulfatase B. While on enzyme replacement therapy and GH therapy, her height increased drastically; her coarse face, joint contracture, snoring, and obstructive sleep apnea improved; urine GAG decreased; and left ventricular mass index was remarkably decreased. We report a novel variant-c.1157C>T (p.Ser386Phe)-of the ARSB gene in a patient with MPS VI; these findings will expand our knowledge of its clinical spectrum and molecular mechanisms.